Alyssum Therapeutics highlights Nature Nanotechnology study on B cell-activating cancer drug

Alyssum Therapeutics said a Nature Nanotechnology paper shows its lead drug candidate AT-1965 can activate B cells to turn immunologically cold tumors hot in preclinical models. The company says the work points to a new solid-tumor immunotherapy approach, and a U.S. clinical trial is already underway.

Why it matters: - Alyssum Therapeutics is positioning B cell activation as a new cancer-treatment strategy after current immunotherapy approaches have largely focused on T cells. - The company says the approach could open a new path for patients with solid tumors, including use as a single agent or in combination with other immunotherapies. - The publication also points to possible long-term immune memory, which could help reduce tumor relapse.

What happened: - Alyssum Therapeutics announced the publication of a study in Nature Nanotechnology titled "Activating a B cell immune response regresses immunologically cold tumors". - The study identifies CMTR2 as a therapeutic target in cancer. - In preclinical models, the company's drug candidate AT-1965 regressed immunologically cold tumors and prevented tumor relapse. - The AT-1965 clinical trial is open at multiple sites in the U.S. under NCT06234098.

The details: - Inhibiting CMTR2 causes cancer cells to produce RNA that resembles viral RNA. - That viral-like RNA triggers B cells to attack cancer cells. - Alyssum said AT-1965 is a first-in-class inhibitor of CMTR2. - The company said AT-1965 showed superior single-agent efficacy in preclinical models. - Alyssum also said AT-1965 showed strong synergy with PD-1 inhibition in lung cancer. - The company describes AT-1965 as a first-in-class small molecule liposomal formulation targeting CMTR2 in cancer cells. - Alyssum said B cells can act as antigen-presenting cells, secrete antibodies that recruit innate immune cells, and release cytokines that create an inflamed tumor environment.

Between the lines: - The study suggests Alyssum is trying to move immunotherapy beyond T cell-only activation. - The company is betting that recruiting B cells to tumors could help convert immune-resistant cancers into ones more visible to the immune system. - Patrick Soon-Shiong said the publication bridges techniques from quantum mechanics to single-cell analysis and genetic knockouts to develop the first drug that activates B cells. - Richard Fahrner said the findings reflect an efficacy plateau in current immunotherapy and that B-cell mobilization could break through that limit.

What's next: - The ongoing U.S. trial will test AT-1965 in patients with solid tumors. - Alyssum said the program could advance as a single therapy or in combination with PD-1 inhibitors. - The company also said the publication supports further development of first-in-class molecules that modulate B cell immune response for oncology and immunological conditions.

The bottom line: - Alyssum is advancing a B cell-focused immunotherapy thesis with early preclinical data, a peer-reviewed publication, and an active clinical trial now in motion.